Managing Hypertension – Using Single Tablet Regimens

(Medical News Today) — The Journal of Medical Economics reveals that hypertensive patients who are treated with a single tablet regimen (STR) as part of their therapy had a considerable reduction in serious cardiovascular events at a neutral cost as compared with individual component therapies.

The data was based on a retrospective analysis of the UK THIN database and demonstrated that the treatment was cost neutral to the NHS due to the additional drug acquisition costs for STR therapy being offset by a reduction in hospital admissions and initial referral costs for cardiovascular events.

According to Dr Jonathan Belsey’s analysis, over a 5-year period, only 8.3% of hypertensive patients who received a STR as part of their therapy suffered from serious cardiovascular events, compared with 13.6% of patients on individual component therapies.

STR was defined as any combination tablet that incorporated two or more agents from different classes of antihypertensive treatment.

The average annual management cost over a period of five years was calculated at £191.49 per STR patient and at £189.35 for patients treated with single component therapies. Given that the study was based on a retrospective cohort, the researchers were unable to identify the reasons for individual prescriptions, as some prescriptions may have been issued for other reasons rather than hypertension.

The study results support findings from a US meta-analysis, which revealed hospital admissions for cardiovascular events were considerably lower for patients treated with STRs compared with those who received individual component therapy.


1 Star2 Stars3 Stars4 Stars5 Stars (1 votes, average: 5.00 out of 5)
Loading ... Loading ...